{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:51:26Z","timestamp":1792097486063,"version":"4.4.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,10,9]],"date-time":"2012-10-09T00:00:00Z","timestamp":1349740800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1007\/s00280-012-1986-8","type":"journal-article","created":{"date-parts":[[2012,10,8]],"date-time":"2012-10-08T10:18:52Z","timestamp":1349691532000},"page":"115-121","source":"Crossref","is-referenced-by-count":68,"title":["Phase I study of 5-aza-2\u2032-deoxycytidine in combination with valproic acid in non-small-cell lung cancer"],"prefix":"10.1007","volume":"71","author":[{"given":"B. F.","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. J.","family":"Karpenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Aimiuwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Villalona-Calero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. K.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. R.","family":"Grever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. A.","family":"Otterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,10,9]]},"reference":[{"issue":"2","key":"1986_CR1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","volume":"346","author":"JH Schiller","year":"2002","unstructured":"Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346(2):92\u201398. doi: 10.1056\/NEJMoa011954","journal-title":"N Engl J Med"},{"issue":"13","key":"1986_CR2","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1200\/JCO.2001.19.13.3210","volume":"19","author":"K Kelly","year":"2001","unstructured":"Kelly K, Crowley J, Bunn PA Jr, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB, Gandara DR (2001) Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non\u2013small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 19(13):3210\u20133218","journal-title":"J Clin Oncol"},{"issue":"3","key":"1986_CR3","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.lungcan.2010.08.018","volume":"70","author":"EM Bertino","year":"2010","unstructured":"Bertino EM, Otterson GA (2010) Benefits and limitations of antiangiogenic agents in patients with non-small cell lung cancer. Lung Cancer 70(3):233\u2013246. doi: 10.1016\/j.lungcan.2010.08.018","journal-title":"Lung Cancer"},{"issue":"21","key":"1986_CR4","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129\u20132139. doi: 10.1056\/NEJMoa040938","journal-title":"N Engl J Med"},{"issue":"11","key":"1986_CR5","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMra0707704","volume":"358","author":"F Ciardiello","year":"2008","unstructured":"Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358(11):1160\u20131174. doi: 10.1056\/NEJMra0707704","journal-title":"N Engl J Med"},{"issue":"10","key":"1986_CR6","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/nrc3130","volume":"11","author":"SB Baylin","year":"2011","unstructured":"Baylin SB, Jones PA (2011) A decade of exploring the cancer epigenome\u2014biological and translational implications. Nat Rev Cancer 11(10):726\u2013734. doi: 10.1038\/nrc3130","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"1986_CR7","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.cell.2007.01.029","volume":"128","author":"PA Jones","year":"2007","unstructured":"Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128(4):683\u2013692. doi: 10.1016\/j.cell.2007.01.029","journal-title":"Cell"},{"issue":"5","key":"1986_CR8","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1053\/j.seminoncol.2005.07.007","volume":"32","author":"DS Schrump","year":"2005","unstructured":"Schrump DS, Nguyen DM (2005) Targeting the epigenome for the treatment and prevention of lung cancer. Semin Oncol 32(5):488\u2013502. doi: 10.1053\/j.seminoncol.2005.07.007","journal-title":"Semin Oncol"},{"issue":"8","key":"1986_CR9","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrg1655","volume":"6","author":"KD Robertson","year":"2005","unstructured":"Robertson KD (2005) DNA methylation and human disease. Nat Rev Genet 6(8):597\u2013610. doi: 10.1038\/nrg1655","journal-title":"Nat Rev Genet"},{"issue":"2","key":"1986_CR10","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nrc1799","volume":"6","author":"SB Baylin","year":"2006","unstructured":"Baylin SB, Ohm JE (2006) Epigenetic gene silencing in cancer\u2014a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6(2):107\u2013116. doi: 10.1038\/nrc1799","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"1986_CR11","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/j.seminoncol.2005.07.008","volume":"32","author":"RL Momparler","year":"2005","unstructured":"Momparler RL (2005) Epigenetic therapy of cancer with 5-aza-2\u2032-deoxycytidine (decitabine). Semin Oncol 32(5):443\u2013451. doi: 10.1053\/j.seminoncol.2005.07.008","journal-title":"Semin Oncol"},{"issue":"32","key":"1986_CR12","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1200\/JCO.2009.22.1291","volume":"27","author":"AA Lane","year":"2009","unstructured":"Lane AA, Chabner BA (2009) Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27(32):5459\u20135468. doi: 10.1200\/JCO.2009.22.1291","journal-title":"J Clin Oncol"},{"issue":"1","key":"1986_CR13","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/1078-0432.CCR-07-0135","volume":"14","author":"DS Schrump","year":"2008","unstructured":"Schrump DS, Fischette MR, Nguyen DM, Zhao M, Li X, Kunst TF, Hancox A, Hong JA, Chen GA, Kruchin E, Wright JJ, Rosing DR, Sparreboom A, Figg WD, Steinberg SM (2008) Clinical and molecular responses in lung cancer patients receiving Romidepsin. Clin Cancer Res 14(1):188\u2013198. doi: 10.1158\/1078-0432.CCR-07-0135","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1986_CR14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2174\/1568011033482440","volume":"3","author":"WG Zhu","year":"2003","unstructured":"Zhu WG, Otterson GA (2003) The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr Med Chem Anticancer Agents 3(3):187\u2013199","journal-title":"Curr Med Chem Anticancer Agents"},{"issue":"4","key":"1986_CR15","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1586\/14737140.7.4.583","volume":"7","author":"D Marchion","year":"2007","unstructured":"Marchion D, Munster P (2007) Development of histone deacetylase inhibitors for cancer treatment. Expert Rev Anticancer Ther 7(4):583\u2013598. doi: 10.1586\/14737140.7.4.583","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"1986_CR16","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/5047","volume":"21","author":"EE Cameron","year":"1999","unstructured":"Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB (1999) Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21(1):103\u2013107. doi: 10.1038\/5047","journal-title":"Nat Genet"},{"issue":"39","key":"1986_CR17","doi-asserted-by":"crossref","first-page":"36734","DOI":"10.1074\/jbc.M101287200","volume":"276","author":"CJ Phiel","year":"2001","unstructured":"Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276(39):36734\u201336741. doi: 10.1074\/jbc.M101287200","journal-title":"J Biol Chem"},{"issue":"9","key":"1986_CR18","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/annonc\/mdm204","volume":"18","author":"M Candelaria","year":"2007","unstructured":"Candelaria M, Gallardo-Rincon D, Arce C, Cetina L, Aguilar-Ponce JL, Arrieta O, Gonzalez-Fierro A, Chavez-Blanco A, de la Cruz-Hernandez E, Camargo MF, Trejo-Becerril C, Perez-Cardenas E, Perez-Plasencia C, Taja-Chayeb L, Wegman-Ostrosky T, Revilla-Vazquez A, Duenas-Gonzalez A (2007) A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol 18(9):1529\u20131538. doi: 10.1093\/annonc\/mdm204","journal-title":"Ann Oncol"},{"issue":"7","key":"1986_CR19","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1182\/blood.V96.7.2379","volume":"96","author":"M Koshy","year":"2000","unstructured":"Koshy M, Dorn L, Bressler L, Molokie R, Lavelle D, Talischy N, Hoffman R, van Overveld W, DeSimone J (2000) 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood 96(7):2379\u20132384","journal-title":"Blood"},{"issue":"1","key":"1986_CR20","first-page":"249","volume":"61","author":"S Zochbauer-Muller","year":"2001","unstructured":"Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD (2001) Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 61(1):249\u2013255","journal-title":"Cancer Res"},{"issue":"19","key":"1986_CR21","doi-asserted-by":"crossref","first-page":"6241","DOI":"10.1158\/1078-0432.CCR-09-0567","volume":"15","author":"J Lin","year":"2009","unstructured":"Lin J, Gilbert J, Rudek MA, Zwiebel JA, Gore S, Jiemjit A, Zhao M, Baker SD, Ambinder RF, Herman JG, Donehower RC, Carducci MA (2009) A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors. Clinical Cancer Res 15(19):6241\u20136249. doi: 10.1158\/1078-0432.CCR-09-0567","journal-title":"Clinical Cancer Res"},{"issue":"10","key":"1986_CR22","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1182\/blood-2006-03-009142","volume":"108","author":"G Garcia-Manero","year":"2006","unstructured":"Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Wierda WG, Ravandi F, Koller C, Xiao L, Faderl S, Estrov Z, Cortes J, O\u2019Brien S, Estey E, Bueso-Ramos C, Fiorentino J, Jabbour E, Issa JP (2006) Phase 1\/2 study of the combination of 5-aza-2\u2032-deoxycytidine with valproic acid in patients with leukemia. Blood 108(10):3271\u20133279. doi: 10.1182\/blood-2006-03-009142","journal-title":"Blood"},{"issue":"25","key":"1986_CR23","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1200\/JCO.2006.09.4169","volume":"25","author":"W Blum","year":"2007","unstructured":"Blum W, Klisovic RB, Hackanson B, Liu Z, Liu S, Devine H, Vukosavljevic T, Huynh L, Lozanski G, Kefauver C, Plass C, Devine SM, Heerema NA, Murgo A, Chan KK, Grever MR, Byrd JC, Marcucci G (2007) Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 25(25):3884\u20133891. doi: 10.1200\/JCO.2006.09.4169","journal-title":"J Clin Oncol"},{"issue":"2","key":"1986_CR24","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.critrevonc.2006.07.010","volume":"61","author":"Y Oki","year":"2007","unstructured":"Oki Y, Aoki E, Issa JP (2007) Decitabine\u2013bedside to bench. Crit Rev Oncol Hematol 61(2):140\u2013152. doi: 10.1016\/j.critrevonc.2006.07.010","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"1986_CR25","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1532\/IJH97.07034","volume":"86","author":"Y Oki","year":"2007","unstructured":"Oki Y, Issa JP (2007) Treatment options in advanced myelodysplastic syndrome, with emphasis on epigenetic therapy. Int J Hematol 86(4):306\u2013314. doi: 10.1532\/IJH97.07034","journal-title":"Int J Hematol"},{"issue":"5","key":"1986_CR26","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1007\/s00280-006-0225-6","volume":"58","author":"A Hurtubise","year":"2006","unstructured":"Hurtubise A, Momparler RL (2006) Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2\u2032-deoxycytidine (decitabine) on human breast carcinoma cells. Cancer Chemother Pharmacol 58(5):618\u2013625. doi: 10.1007\/s00280-006-0225-6","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"1986_CR27","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1158\/0008-5472.CAN-03-2043","volume":"64","author":"P Atadja","year":"2004","unstructured":"Atadja P, Gao L, Kwon P, Trogani N, Walker H, Hsu M, Yeleswarapu L, Chandramouli N, Perez L, Versace R, Wu A, Sambucetti L, Lassota P, Cohen D, Bair K, Wood A, Remiszewski S (2004) Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. Cancer Res 64(2):689\u2013695","journal-title":"Cancer Res"},{"issue":"12","key":"1986_CR28","doi-asserted-by":"crossref","first-page":"6361","DOI":"10.1158\/0008-5472.CAN-06-0080","volume":"66","author":"SD Gore","year":"2006","unstructured":"Gore SD, Baylin S, Sugar E, Carraway H, Miller CB, Carducci M, Grever M, Galm O, Dauses T, Karp JE, Rudek MA, Zhao M, Smith BD, Manning J, Jiemjit A, Dover G, Mays A, Zwiebel J, Murgo A, Weng LJ, Herman JG (2006) Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 66(12):6361\u20136369. doi: 10.1158\/0008-5472.CAN-06-0080","journal-title":"Cancer Res"},{"issue":"19","key":"1986_CR29","doi-asserted-by":"crossref","first-page":"5777","DOI":"10.1158\/1078-0432.CCR-06-0669","volume":"12","author":"DS Schrump","year":"2006","unstructured":"Schrump DS, Fischette MR, Nguyen DM, Zhao M, Li X, Kunst TF, Hancox A, Hong JA, Chen GA, Pishchik V, Figg WD, Murgo AJ, Steinberg SM (2006) Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res 12(19):5777\u20135785. doi: 10.1158\/1078-0432.CCR-06-0669","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1986_CR30","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1097\/JTO.0b013e3181ec1713","volume":"5","author":"GA Otterson","year":"2010","unstructured":"Otterson GA, Hodgson L, Pang H, Vokes EE (2010) Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304). J Thorac Oncol 5(10):1644\u20131648. doi: 10.1097\/JTO.0b013e3181ec1713","journal-title":"J Thorac Oncol"},{"issue":"6","key":"1986_CR31","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/1078-0432.CCR-10-1893","volume":"17","author":"A Stathis","year":"2011","unstructured":"Stathis A, Hotte SJ, Chen EX, Hirte HW, Oza AM, Moretto P, Webster S, Laughlin A, Stayner LA, McGill S, Wang L, Zhang WJ, Espinoza-Delgado I, Holleran JL, Egorin MJ, Siu LL (2011) Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin\u2019s lymphomas. Clin Cancer Res 17(6):1582\u20131590. doi: 10.1158\/1078-0432.CCR-10-1893","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-012-1986-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-012-1986-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-012-1986-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T15:14:31Z","timestamp":1594739671000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-012-1986-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,9]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["1986"],"URL":"https:\/\/doi.org\/10.1007\/s00280-012-1986-8","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,9]]}}}